Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 37,100 shares, a drop of 45.2% from the December 15th total of 67,700 shares. Approximately 2.8% of the shares of the company are sold short. Based on an average daily volume of 307,000 shares, the days-to-cover ratio is currently 0.1 days.

Sonoma Pharmaceuticals Stock Performance

Shares of SNOA stock traded up $0.04 during trading on Thursday, hitting $2.66. The company had a trading volume of 53,750 shares, compared to its average volume of 43,035. The firm has a market capitalization of $3.56 million, a P/E ratio of -0.53 and a beta of 1.41. Sonoma Pharmaceuticals has a one year low of $2.44 and a one year high of $9.37. The stock’s 50-day moving average price is $2.73 and its 200 day moving average price is $2.12.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.